Modeling enzyme-ligand binding in drug discovery

Janez Konc¹², Samo Lešnik¹ and Dušanka Janežič²*

Abstract
Enzymes are one of the most important groups of drug targets, and identifying possible ligand-enzyme interactions is of major importance in many drug discovery processes. Novel computational methods have been developed that can apply the information from the increasing number of resolved and available ligand-enzyme complexes to model new unknown interactions and therefore contribute to answer open questions in the field of drug discovery like the identification of unknown protein functions, off-target binding, ligand 3D homology modeling and induced-fit simulations.

Keywords: Unknown protein functions, Off-target binding, Drug repositioning, Ligand 3D homology modeling, Induced-fit simulations, ProBiS-ligands web server

Background
Predicting ligands that bind with sufficient strength to a corresponding protein is a challenging task in biochemistry and has significant implication in the discovery of new drug candidates. Many approaches have been developed for this task; the most commonly used being molecular docking [1]. However one of the main drawbacks of classical template-free docking is that every molecule is docked ab initio, and no information from existing similar protein–ligand complexes is taken into consideration. Therefore alternative approaches that use information from existing protein–ligand complexes, which can be obtained from freely-available databases, such as the Protein Data Bank [2] are becoming increasingly important. The main assumption of such approaches is that similar protein binding sites bind similar ligands, and thus a known ligand from one protein can be transposed to a similar binding site in another protein that was previously not known to bind this ligand. Transposition of ligands is based on accurate alignments of three-dimensional amino-acid patterns or of their corresponding functional groups in the proteins’ binding sites; due to their local nature in the binding sites, such alignments may not be possible with standard sequence or structure alignment approaches. Ligand transposition shown in Fig. 1 can thus be a powerful approach, which can be used in pharmaceutical applications such as drug repositioning [3–6], ligand-homology modeling [7–9], induced-fit simulation [10] and binding site prediction [11–13]. Information about the software described in the following sections is available in Table 1.

Function prediction
Proteins interact with one another and with other molecules, mediate metabolic and signaling pathways and thus regulate cellular processes [14]. One of the fundamental tasks of proteins is to act as enzymes [15], i.e., biological catalysts that increase the rate of practically all chemical reactions that are taking place within cells. Due to their central role in biological function, they control mechanisms leading to healthy and diseased states in the organism. However, for a substantial number of proteins, and subsequently enzymes, their functions are not known, therefore an important challenge in structural genomics is the prediction of function of these uncharacterized proteins [16]. While experimental determination of a protein function is still the most reliable way to characterize unknown proteins, it is difficult to prioritize functional experiments among the many possible functions a protein could perform. To guide experimentalist, a number of computer approaches are routinely used to predict protein function. However, many are based on sequence
and overall structural homology [17, 18], consequently often missing similarities when only local binding sites are conserved. The identification of such binding sites on the protein surface is therefore usually the starting point for protein function annotation. Moreover, because knowledge of the binding site location is the prerequisite for molecular docking, binding site identification is often a first step in structure-based drug design.

Based on the idea that proteins with similar local binding sites perform similar function, an algorithm ProBiS and its corresponding web server [19, 20] was developed. ProBiS uses a fast maximum clique algorithm [21] to compare a query protein to members of a database of 3D protein structures and detects with sub-residue precision structurally similar binding sites as patterns of physio-chemical properties on the protein surface. The algorithm thus identifies database proteins that share local structural similarities with the query protein independent of the global protein folds, and generates structure-based alignments for every query protein-database protein pair. Moreover, structural similarity scores are calculated for the query protein surface residues, and are expressed as different colors on the protein’s surface. ProBiS was tested for its binding site detection ability on a set of 39 protein structures and by comparing it to an evolutionary conservation mapping method ConSurf [22] and an energy-based method Q-SiteFinder [23], it was shown that ProBiS outperformed both of the two aforementioned methods. Moreover, to demonstrate ProBiS’ unique ability to detect and align similar binding sites in the absence of global fold similarity, the authors examined 10 pairs of protein structures, where the two members of each pair
exhibited different folds but had known similar binding sites and performed a similar function. ProBiS was compared to three different structural alignment algorithms; DaliLite [24], MolLoc [25] and MultiBind [26]. The comparison between the methods was made by calculating the RMSD between previously identified, similar binding site residues, after the proteins in the pair have been superimposed. ProBiS demonstrated, by far, the lowest average RMSD in comparison to other methods; while also having the ability to align binding sites in an unsupervised fashion, which allows it to perform automatic, large database searches. ProBiS, in combination with molecular dynamics, was also used to propose the function to a protein of unknown activity—the Tm1631 protein from T. maritima [27]. The binding site comparison revealed numerous similarities with nucleotide binding sites; including specifically, a DNA-binding site of endonuclease IV. Based on the superimposition of Tm1631 with endonuclease IV, a hypothetical model of the Tm1631-DNA complex was constructed. This model was validated with the use of CHARMM [28, 29] to perform a molecular dynamics simulation, which showed that the interactions predicted by the Tm1631-DNA model correspond well to those known to be importation in the endonuclease IV-DNA complex. The simulation also showed that the binding free energies of the model and the known complex were in close agreement. The authors thus concluded that the Tm1631 protein could be a DNA binding enzyme with endonuclease activity. ProBiS was also used to identify conserved binding sites on hemagglutinin, a protein responsible for binding the influenza virus to cells [30]. A local structural superimposition across all subtypes and strains of hemagglutinin available in the PDB at the time, revealed a new conserved region on hemagglutinin, a potential conserved target for influenza drug and vaccine development.

Another freely-accessible web server for binding site annotation—GalaxySite [31] combines binding site information from known proteins with molecular docking to predict ligand binding amino acid residues. Initially the server uses HHsearch [32] to search for similar protein–ligand complexes in the structural databases. The highest ranking ligands are transposed from the target to the query structure where their binding conformation is optimized using the LigDockCSA protein–ligand docking program [33]. Binding-site residues are then identified based on their proximity to the docked ligand. GalaxySite was extensively tested on different ligand binding prediction test sets, on which it showed superior or similar performance compared to other state of the art prediction methods.

Moreover, Surflex-PSIM [34], a novel method combining initial binding site recognition with subsequent binding site comparisons has been developed. The newest version of Surflex-PSIM is able to automatically detect ligand binding pockets and compare them, based on their surface similarity to other known proteins. The method was tested on a set of eight proteins, whose function was unknown at the time of the testing. All of the eight proteins were screened against ~60,000 ligand binding sites from the PDB. Surflex-PSIM correctly identified functional matches that predated query protein biochemical annotation for five out of the eight proteins. In addition,
Drug repositioning

Drug repositioning or repurposing is a principle of discovering novel therapeutic indications for existing approved drugs, which provides an alternative and cost-efficient strategy of discovering disease therapeutics [36]. A prerequisite for drug repurposing is drug promiscuity (polypharmacology), which is a drug’s ability to bind to several different targets. A recent study suggests that the most important factor contributing to the observed promiscuity of many drugs is the local binding site similarities between different protein targets [3]. It was discovered that off-target binding is the major cause of unwanted side-effects for many drugs from a wide range of therapeutic areas [37]. Therefore binding site comparison methods may have an important role in identifying the polypharmacological activity of molecules.

Recently, an integrated computational method for proteome-wide off target identification, abbreviated POP (proteome-wide off-target pipeline) was developed. POP combines ligand binding site comparison analysis, protein–ligand docking and electrostatic potential calculation to identify possible promiscuous protein–ligand interactions throughout the proteasome. The core component of this method is the well-established software for binding site comparison SMAP [38, 39]. SMAP initially detects the location and boundary of the query protein ligand binding site. The binding site is then compared against target 3D protein structures using a sequence-order independent profile–profile alignment (SOIPPA) algorithm [39] that is able to detect similar binding sites between structurally unrelated proteins. The next step is the superimposition (and subsequent ligand transposition) of the query binding site to the top scoring target binding sites. The transposed ligand binding pose serves as the starting structure in the following docking and scoring. The highest scoring protein–ligand complexes reflect the possible off-targets of the ligand. In addition, the electrostatic potential binding energy and similarity between the binding sites can be calculated based on the binding pose of the ligand. POP was applied to identify possible off-targets of the HIV protease inhibitor nelfinavir. The protein–ligand complex of HIV protease bound with nelfinavir (PDB code: 1ohr) was searched against a variety of human protein structures and models. Top ranked hits contained multiple members of the protein kinase superfamily, most of which are on the upstream of the Akt1 and Akt2 enzymes in the Akt pathway [40], which is in correlation with the experimentally observed anti-cancer effect of nelfinavir.

Ligand 3D homology modeling

Virtual screening is a widely used approach in the early stage of pharmaceutical discovery [41]. In practice, we distinguish two broad categories of virtual screenings: (a) ligand based and (b) structure based [42, 43]. Ligand based virtual screening is relatively fast, however the method requires previously known ligands that bind to a certain target; this hinders its universality and large-scale application. On the other hand, structure based virtual screening uses the structure of a target/target binding site, to which it docks potential drug molecules and evaluates the binding likelihood using different scoring functions; its main advantage is that no prior knowledge of known active ligands is needed. The main disadvantage of structure based virtual screening is the requirement for high-resolution structures of target proteins, which are in many cases not available, especially for G-protein coupled receptors and ion-channels [44]. However, with increasing number of holo protein structures deposited in large protein databases, a novel type of virtual screening, termed ligand-homology modeling (LHM) is gaining recognition [7–9, 45]. LHM is a knowledge-based approach that relies on the fact that evolutionary related proteins share similar functions and thus bind similar ligands, and that this information can be used to predict ligand-target interactions. In general, LHM algorithms start with identifying and aligning similar binding sites between a query and target database holo proteins, which is then followed by transposing the ligands from target proteins to the query binding site.

One of the main shortcomings of the LHM is the need for sufficient numbers of holo proteins that share similar binding sites to the query protein. To overcome this serious disadvantage, a novel combined ligand homology modeling approach, FINDSITEcomb was developed [46, 47]. FINDSITEcomb is a composite approach consisting of the FINDSITEflh and the FINDSITEX algorithms. While the former still uses known holo proteins deposited in protein databases, FINDSITEX circumvents this requirement by employing homology modeling to model
structures of target proteins not yet available in protein databases. The FINDSITEfilt algorithm works by initially finding template holo protein structures that are evolutionary related to the target structure from the PDB database. Next, a heuristic structure–pocket alignment method is used to superimpose template pockets to the target structure and a sequence dependent scoring function to rank the best templates (based on the structure–pocket alignment) from whose their corresponding ligands will be used as reference small molecules in subsequent ligand based virtual screening. FINDSITEX on the other hand, as mentioned, employs homology modeling methods to model structures of template proteins, which are then aligned and compared to target proteins using a global structure alignment method. Similar as in FINDSITEfilt, the ligands of the top ranked templates are used as reference small molecules for ligand based virtual screening, where the appropriate template ligands are obtained from the DrugBank [48] and ChEMBL [49] databases. By combining the scores obtained from FINDSITEfilt and FINDSITEX ligand based virtual screening runs, the method evaluates the likelihood of each compound of being a true active. The performance of FINDSITEcomb was thoroughly evaluated both on the directory of useful decoys (DUD) database [50] and experimentally on eight different protein targets [51]. In the former evaluation, FINDSITEcomb outperformed, in most cases, established docking methods, such as AUTODOCK Vina [52] and DOCK 6 [53]; demonstrating significantly higher enrichment factors and areas under the ROC curves. Testing FINDSITEcomb on eight different proteins with subsequent experimental ligand binding evaluations, the authors identified 47, mostly novel small molecules with µM or better affinities. Of those, 10 ligands showed affinities in the nanomolar range (for dihydroypholate reductase from E. coli and two mammalian protein tyrosine phosphatases).

Also a recently developed, freely-available web server, which enables ligand homology modeling, is ProBiS-ligands (Fig. 2) [45], a method that uses a fast maximum clique algorithm [21] to screen the non-redundant PDB database, to find structurally similar target binding sites to user provided input query protein, independent of their sequence or global structural similarity. Ligands which are bound in the identified similar binding sites are transposed to the query protein by rotation and translation of their atoms’ coordinates generated by the superimposition matrices acquired from the initial superposition of the query and target proteins. ProBiS-ligands is able to predict protein–protein, protein-small molecules, protein-nucleic acid, and protein-ion interactions. The performance of the web server was assessed with a test set [54] containing 500 proteins models and their corresponding experimental structures. The success of ligand prediction was measured by calculating the correspondence between the predicted ligand binding sites, i.e. query residues <4 Å from the first cluster of predicted small molecules or ions and the actual known binding sites for each of the 500 proteins. This binding site prediction results were evaluated with the Matthews correlation coefficient, precision and recall (for definitions of each see, e.g. [54]). Moreover to assess the similarity of predicted ligands with the actual ones, each highest scoring (by Z-score) predicted ligand from the first small molecule or ion cluster was compared with the actual known ligands using an in-house developed 2D molecular graph matching algorithm. Ligand similarities were expressed as the Tanimoto coefficients and were averaged across all comparisons. ProBiS-ligands showed encouraging results, with the average ligand similarity Tanimoto coefficient of 0.61 (0.55) and MCC of 0.54 (0.41) (the values in parenthesis are for the modeled structure). Even when all templates sharing >10 % sequence identity with the target were removed (to simulate the lack of similar templates that frequently occur in real world simulations), reasonable predictions for the experimental protein structures were still possible with the average ligand similarity of 0.40 and MCC of 0.28. In contrary, for protein models, templates of at least 20–30 % sequence identity were required to obtain similar accuracy.

As discussed, an important drawback in classical screening methods is that large molecular databases (usually containing millions of compounds) have to be screened to find potential drug candidates. Given this difficulty of thoroughly exploring the chemical–space of drug like molecules, fragment-based approaches have emerged. Fragments refer to low-molecular-weight molecules, usually 140–300 Daltons in weight [55, 56], that can be connected to form larger molecules. It was shown that fragments have higher hit rates compared to large, complex drug-like molecules because they are less likely to possess suboptimal interactions or physical clashes with the target [57]. Moreover, a fragment library can provide a more compact and tractable basis set for chemical space than standard small molecule libraries [58]. A novel knowledge-based fragment binding predictor FragFEATURE was developed that overcomes many limitations of the existing fragment binding predictors [59]. Using information from the PDB, the authors preliminarily created a database linking local protein structural environments to the small molecule fragments they bind. Given the structural environments from a target protein, FragFEATURE compares them to the database to find similar structural environments and identifies statistically preferred fragments. The results demonstrated the method’s ability to rediscover fragments corresponding
to the ligands bound with 74 % precision and 82 % recalls on average. For many protein targets, FragFEATURE was able to identify high scoring fragments that are substructures to known inhibitors. Such predicted fragments can serve as inputs to fragment-based drug design or serve as refinement criteria for creating target-specific compound libraries for experimental or computational screening.

**Induced-fit simulation**

One of the main downsides of many established molecular docking algorithms is their inability to consider binding site flexibility [60]. This can present a serious drawback, especially when only a crystal structure without its corresponding ligands is available. Such a protein can be locked in a conformation that is a poor representation of an actual spatial arrangement of binding site amino acid residues upon ligand binding [61], making it a poor candidate for target-based virtual screening studies.

To overcome difficulties where the binding pocket conformation is unsuitable for docking, our group developed a new simple and fast approach to simulate the induced-fit conformational changes of protein structures upon binding. For example, the UDP-N-acetylgalactosamine enolpyruvyl transferase enzyme (MurA, PDB code: 1gae) from *E. coli* exists in the PDB only as apoprotein and our initial docking study with the docking program FRED software [62] showed that most drug-like molecules were unable to dock in this binding site without exhibiting severe clashes with the amino acid residues. To circumvent this problem, ProBiS-ligands [45] was used in combination with standard molecular minimization algorithms. With the *E. coli* MurA crystal structural as input, ProBiS-ligands enabled the identification and transposition of a ligand (PDB ligand code: TAV) bound originally in a binding site of the MurA enzyme from *E. cloaca* (PDB code: 1ybg). With the new-found ligand transposed to the query binding site and all the original ligands and water molecules removed, molecular minimization was performed on this complex to obtain an open binding site structure of the enzyme that was more suitable for docking. The docking was then repeated on this opened binding site against the ZINC Drugs Now database [63], which yielded very
good inhibitors of MurA enzyme as three of the highest scoring compounds that were biochemically tested for their inhibitory ability showed lower than 1 μM IC$_{50}$ values and are now subject for further optimization and research (in preparation).

**Conclusion**

Ever increasing numbers of 3D holo enzyme structures deposited in large protein databases enable that the information of known enzyme-ligand interactions be used in predicting and evaluating novel complexesa—a key step in drug discovery. Knowledge-based computational methods that apply this information have been successfully used in a wide variety of fields that are of interest to pharmaceutical research; from drug repositioning to simulating induced-fit upon ligand binding. Increased usage of knowledge-based methods for modeling ligand-enzyme interactions is expected in the near future, especially in the early stages of drug discovery processes.

**Authors’ contributions**

JK, SL, DJ wrote the manuscript. All authors read and approved the final manuscript.

**Author details**

1. National Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia.
2. Faculty of Mathematics, Natural Sciences and Information Technologies, University of Primorska, Glagoljaška 8, SI-6000 Koper, Slovenia.

**Acknowledgements**

Financial support through Grants P1-0002, J1-6743 and L1-6745 of the Ministry of Higher Education, Science and Technology of Slovenia and Slovenian Research Agency is acknowledged.

**Compliance with ethical guidelines**

The authors declare that they have no competing interests.

**Competing interests**

The authors declare that they have no competing interests.

**Received: 21 July 2015 Accepted: 29 September 2015**

**Published online:** 06 October 2015
38. Xie L, Bourne PE (2007) A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites. BMC Bioinform 8:59
39. Xie L, Bourne PE (2008) Detecting evolutionary relationships across existing fold space, using sequence order-independent profile–profile alignments. Proc Nat Acad Sci USA 105:5441–5446
40. Xie L et al (2011) Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of Nelfinavir. PLoS Comput Biol 7:e1002037
41. Chen H et al (2006) On evaluating molecular-docking methods for pose prediction and enrichment factors. J Chem Inf Model 46:401–415
42. Srinivas Reddy A et al (2007) Virtual screening in drug discovery—a computational perspective. Curr Protein Pept Sci 8:329–351
43. Schneider G (2010) Virtual screening: an endless staircase? Nat Rev Drug Discov 9:273–276
44. Carpenter EP et al (2008) Overcoming the challenges of membrane protein crystallography. Curr Opin Struct Biol 18:581–586
45. Konc J, Janežič D (2014) ProBiS-ligands: a web server for prediction of ligands by examination of protein binding sites. Nucleic Acids Res 42:W215–W220
46. Zhou H, Skolnick J (2013) FINDSITEcomb: a Threading/structure-based, proteomic-scale virtual ligand screening approach. J Chem Inf Model 53:230–240
47. Zhou H, Skolnick J (2012) FINDSITEX: a structure-based, small molecule virtual screening approach with application to all identified human GPCRs. Mol Pharm 9:1775–1784
48. Wishart DS et al (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668–D672
49. Gaulton A et al (2011) CHEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. doi:10.1093/nar/gkr777
50. Huang N et al (2006) Benchmarking sets for molecular docking. J Med Chem 49:6789–6801
51. Srinivasan B et al (2014) Experimental validation of FINDSITEcomb virtual ligand screening results for eight proteins yields novel nanomolar and micromolar binders. J Cheminform 6:16
52. Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31:455–461
53. Brozell SR et al (2012) Evaluation of DOCK 6 as a pose generation and database enrichment tool. J Comput Aided Mol Des 26:749–773
54. Yang J et al (2013) Protein–ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. Bioinformatics 29:2588–2595
55. Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6:211–219
56. Zhou JZ (ed) (2011) Fragment-based drug design—Springer. Humana Press, New york
57. Hann MM et al (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41:856–864
58. Carr RAE et al (2005) Fragment-based lead discovery: leads by design. Drug Discov Today 10:987–992
59. Tang GW, Altman RB (2014) Knowledge-based fragment binding prediction. PLoS Comput Biol 10:e1003589
60. Guedes IA et al (2013) Receptor–ligand molecular docking. Biophys Rev 6:75–87
61. Sharma H et al (2014) Virtual screening reveals allosteric inhibitors of the Toxoplasma gondii thymidylate synthase–dihydrofolate reductase. Bioorg Med Chem Lett 24:1232–1235
62. McGann M (2011) FRED pose prediction and virtual screening accuracy. J Chem Inf Model 51:578–596
63. Irwin JJ et al (2012) ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 52:1757–1768

Open access provides opportunities to our colleagues in other parts of the globe, by allowing anyone to view the content free of charge.

“Open access provides opportunities to our colleagues in other parts of the globe, by allowing anyone to view the content free of charge.”

W. Jeffery Hurst, The Hershey Company.

- available free of charge to the entire scientific community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours—you keep the copyright

Submit your manuscript here:
http://www.chemistrycentral.com/manuscript/